News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Oladayo Oyebanji

Articles by Oladayo Oyebanji

145 Racial Differences in Outcomes and Health Care Utilization Among Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Analysis

144 A Comparative Analysis of Pregnancy-Related Breast Cancer Outcomes Versus Non-Pregnant Breast Cancer Patients—A TriNetX Real-World Analysis

ByUchenna M. Amaechi,Samrawit Zinabu,Chiugo Okoye,Oladayo Oyebanji,Chinemerem M. Emeasoba,Miriam Michael

April 29th 2026

145 Racial Differences in Outcomes and Health Care Utilization Among Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Analysis

145 Racial Differences in Outcomes and Health Care Utilization Among Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Analysis

ByUchenna M. Amaechi,Kenneth Ssebambulidde,Chiugo Okoye,Oladayo Oyebanji,Chinemerem M. Emeasoba,Miriam Michael

April 28th 2026

Latest Updated Articles

145 Racial Differences in Outcomes and Health Care Utilization Among Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Analysis
April 28th 2026

Trending on CancerNetwork

Capivasertib Combo Earns FDA Approval in PTEN-Deficient Metastatic HSPC

Ziftomenib Plus 7+3 Yields High Response Rates in Newly Diagnosed AML

Pirtobrutinib Plus Venetoclax/Rituximab Improves PFS in Pretreated CLL

Pirtobrutinib Regimen May Offer Prolonged Remissions in Pretreated CLL

Favezelimab Combo Boosts PFS vs Chemo in PD-1–Refractory Hodgkin Lymphoma